| Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, ... Annals of oncology 29 (4), 895-902, 2018 | 367 | 2018 |
| Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis I Pastushenko, F Mauri, Y Song, F de Cock, B Meeusen, B Swedlund, ... Nature 589 (7842), 448-455, 2021 | 326 | 2021 |
| Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial L Buisseret, S Pommey, B Allard, S Garaud, M Bergeron, I Cousineau, ... Annals of oncology 29 (4), 1056-1062, 2018 | 190 | 2018 |
| Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach Y Bareche, L Buisseret, T Gruosso, E Girard, D Venet, F Dupont, ... JNCI: Journal of the National Cancer Institute 112 (7), 708-719, 2020 | 176 | 2020 |
| The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data I Bozovic-Spasojevic, D Zardavas, S Brohée, L Ameye, D Fumagalli, ... Clinical Cancer Research 23 (11), 2702-2712, 2017 | 133 | 2017 |
| Immune infiltration in invasive lobular breast cancer C Desmedt, R Salgado, M Fornili, G Pruneri, G Van den Eynden, ... JNCI: Journal of the National Cancer Institute 110 (7), 768-776, 2018 | 126 | 2018 |
| CD73 promotes resistance to HER2/ErbB2 antibody therapy M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ... Cancer research 77 (20), 5652-5663, 2017 | 112 | 2017 |
| Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy M Ignatiadis, G Van den Eynden, S Roberto, M Fornili, Y Bareche, ... JNCI: Journal of the National Cancer Institute 111 (1), 69-77, 2019 | 79 | 2019 |
| Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors J Jeschke, E Collignon, C Al Wardi, M Krayem, M Bizet, Y Jia, S Garaud, ... Nature cancer 2 (6), 611-628, 2021 | 55 | 2021 |
| Leveraging big data of immune checkpoint blockade response identifies novel potential targets Y Bareche, D Kelly, F Abbas-Aghababazadeh, M Nakano, PN Esfahani, ... Annals of Oncology 33 (12), 1304-1317, 2022 | 53 | 2022 |
| Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer I Nederlof, D De Bortoli, Y Bareche, B Nguyen, M De Maaker, GKJ Hooijer, ... Breast cancer research 21, 1-13, 2019 | 47 | 2019 |
| CD73 inhibits cGAS–STING and cooperates with CD39 to promote pancreatic cancer C Jacoberger-Foissac, I Cousineau, Y Bareche, D Allard, P Chrobak, ... Cancer immunology research 11 (1), 56-71, 2023 | 45 | 2023 |
| MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries C Alexandri, B Stamatopoulos, F Rothé, Y Bareche, M Devos, ... Scientific reports 9 (1), 9636, 2019 | 37 | 2019 |
| The footprint of the ageing stroma in older patients with breast cancer B Brouwers, D Fumagalli, S Brohee, S Hatse, O Govaere, G Floris, ... Breast Cancer Research 19, 1-14, 2017 | 32 | 2017 |
| Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer B Nguyen, I Veys, S Leduc, Y Bareche, S Majjaj, DN Brown, B Boeckx, ... JNCI: Journal of the National Cancer Institute 111 (7), 742-746, 2019 | 25 | 2019 |
| NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation F Mauri, C Schepkens, G Lapouge, B Drogat, Y Song, I Pastushenko, ... Nature cancer 2 (11), 1152-1169, 2021 | 24 | 2021 |
| CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial F Rothé, M Maetens, G Rouas, M Paesmans, M Van den Eynde, ... BMC cancer 19, 1-7, 2019 | 22 | 2019 |
| High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer Y Bareche, S Pommey, M Carneiro, L Buisseret, I Cousineau, P Thebault, ... Journal for ImmunoTherapy of Cancer 9 (3), e001965, 2021 | 21 | 2021 |
| The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group M Maetens, D Brown, A Irrthum, P Aftimos, G Viale, S Loibl, JF Laes, ... NPJ Breast Cancer 3 (1), 23, 2017 | 15 | 2017 |
| Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma B Allard, C Jacoberger-Foissac, I Cousineau, Y Bareche, L Buisseret, ... Cell Reports Medicine 4 (9), 2023 | 12 | 2023 |